Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
27 Junho 2022 - 8:00AM
Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company
committed to discovering and delivering the next generation of
precision cancer medicines, today announced that the company was
added to the Russell 2000®, Russell 3000® and Russell Microcap®
Indexes, effective after the U.S. market closed on June 24, 2022,
as part of the 2022 Russell indexes annual reconstitution.
“Our addition to the Russell indexes reflects the growing
interest in Tango over the past 12 months as we advanced our lead
asset, TNG908, into the clinic while also focusing on expanding our
pipeline through the announcement of additional development
candidates,” said Barbara Weber, M.D., President and Chief
Executive Officer of Tango Therapeutics. “Inclusion in these
indexes will expand our visibility in the investment community, and
with our strong pipeline and anticipated development milestones,
Tango is well positioned to attract new investors in the coming
quarters.”
The Russell 3000® Index is a market capitalization-weighted
equity index that tracks the performance of the largest 3,000 U.S.
stocks. Membership in the U.S. all-cap Russell 3000® Index, which
remains in place for one year, means automatic inclusion in the
large-cap Russell 1000® Index or small-cap Russell 2000® Index as
well as the appropriate growth and value style indexes. Membership
in the Russell Microcap® Index, which remains in place for one
year, means automatic inclusion in the appropriate growth and value
style indexes. Membership of the Russell indexes is primarily
determined by objective, market-capitalization rankings and style
attributes. Russell indexes are widely used by investment managers
and institutional investors for index funds and as benchmarks for
active investment strategies.
About Tango Therapeutics
Tango Therapeutics is a biotechnology company dedicated to
discovering novel drug targets and delivering the next generation
of precision medicine for the treatment of cancer. Using an
approach that starts and ends with patients, Tango leverages the
genetic principle of synthetic lethality to discover and develop
therapies that take aim at critical targets in cancer. This
includes expanding the universe of precision oncology targets into
novel areas such as tumor suppressor gene loss and their
contribution to the ability of cancer cells to evade immune cell
killing. For more information, please visit www.tangotx.com.
Investor Contact:Sam Martin/Michael BarronArgot
Partnerstango@argotpartners.com
Media Contact:Joshua R. Mansbach Argot Partners
tango@argotpartners.com
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Tango Therapeutics (NASDAQ:TNGX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024